Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s (NASDAQ:BIIB) ...

Sage stock collapsed to a record low. Please watch the video at Investors.com - How To Sell Stocks: Long-Term Trend Lines Wedbush analyst Laura Chico says it's hard to tell whether the drug failed ...

Biogen's $3 billion alliance with Sage Therapeutics has suffered another setback after their drug for essential tremor failed to move the needle in a phase 2 study. Topline results from the ...

In return Sage gets $1.525 billion upfront – $875 million in cash and a $650 million equity investment – as well as potential milestones of $1.6 billion if both drugs meet their development ...

This shakeup came as Sage decided to focus resources on its ongoing launch of its approved drug Zurzuvae for postpartum depression, as well as to “focus pipeline development efforts” in ...

There's rosemary, that's for remembrance,' says Ophelia in Shakespeare's Hamlet. So it is fitting that researchers would study a compound found in rosemary and sage -- carnosic acid -- for its impact ...